Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns

Bibliography

• Gatta G, Mallone S, van der Zwan JM, et al. Cancer prevalence estimates in Europe at the beginning of. 2000. Ann Oncol 2013;24:1660-6
   PubMed Web of Science ®Google Scholar
• Greif JM. Mammographic screening for breast cancer: an invited review of the benefits and costs. Breast 2010;19(4):268-72
   PubMed Web of Science ®Google Scholar
• Ademuyiwa FO, Edge SB, Erwin DO, et al. Breast cancer racial disparities: unanswered questions. Cancer Res 2011;71(3):640-4
   PubMed Web of Science ®Google Scholar
• Collins IM, Milne RL, Weideman PC, et al. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers. Med J Aust 2013;199(10):680-3
   PubMed Web of Science ®Google Scholar
• Varela-Rey M, Woodhoo A, Martinez-Chantar ML, et al. Alcohol, DNA methylation, and cancer. Alcohol Res 2013;35(1):25-35
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. systemic therapy for hepatocellular carcinoma(HCC); from bench to bedside. J Egypt Natl Canc Inst 2013;25(4):165-71
   PubMedGoogle Scholar
• Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206-23
   PubMed Web of Science ®Google Scholar
• Senkus S, Kyriakides F, Penault-Llorca et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi7-vi23
   PubMed Web of Science ®Google Scholar
• Søgaard M, Thomsen RW, Bossen KS, et al. The impact of comorbidity on cancer survival: a review. Clin Epidemiol 2013;5(Suppl 1):3-29. eCollection 2013
   PubMedGoogle Scholar
• Cardoso F, Loibl S, Pagani O, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer 2012;48(18):3355-77
   PubMed Web of Science ®Google Scholar
• Mandelblatt JS, Hurria A, McDonald BC, et al. Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know? Semin Oncol 2013;40(6):709-25
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Elsayed ZA. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci 2013;58(12):3389-96
   PubMed Web of Science ®Google Scholar
• National Center for Health and Statistics: tables on trends in health and aging; life expectancy. Available from: www.cdc.gov [Accessed on 25 May2014]
   Google Scholar
• Available from: http://eprognosis.ucsf.edu [Accessed on 7 August 2014]
   Google Scholar
• Molina-Garrido MJ, Guillen-Ponce C. Comparison of two frailty screening told in older women with early breast cancer. Crit Rev Oncol Hematol 2009;79:51-64
   Web of Science ®Google Scholar
• Hurria A, Wong FL, Villaluna D, et al. Role of age and health in treatment recommendations for older adults with breast cancer: the prespective of oncologists and primary care providers. J Clin Oncol 2008;26:5386-92
   PubMed Web of Science ®Google Scholar
• Kornblith AB, Kemeny M, Peterson BL, et al. Survey of oncologists’ perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002;95:989-96
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11(1):44-7
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer- treatment trials. N Engl J Med 1999;341:2061-7
   PubMed Web of Science ®Google Scholar
• Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29:3457-65
   PubMed Web of Science ®Google Scholar
• Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012;118(13):3377-86
   PubMed Web of Science ®Google Scholar
• NCCN breast cancer guidelines, v. 2. 2014. Available from: www.nccn.org/professionals/physician_gls/pdf/breast.pdf [Accessed on 13 February 2014]
   Google Scholar
• Land LH, Dalton SO, Jensen MB, et al. Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br J Cancer 2012;107(11):1901-7
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. PDQ® breast cancer treatment. National Cancer Institute, Bethesda, MD; 2013. Available from: www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional [Last accessed 13 February 2014]
   Google Scholar
• Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol 2014;91(1):1-8
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Elsayed ZA. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci 2013;58(12):3389-96
   PubMed Web of Science ®Google Scholar
• Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 2014;25(3):611-18
   PubMed Web of Science ®Google Scholar
• Eichholzer M, Huang DJ, Modlasiak A, et al. Impact of body mass index on prognostically relevant breast cancer tumor characteristics. Breast Care (Basel) 2013;8(3):192-8
   PubMed Web of Science ®Google Scholar
• Sanpaolo P, Barbieri V, Genovesi D. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol 2011;37(10):876-82
   PubMed Web of Science ®Google Scholar
• Wiens AL, Martin SE, Bertsch EC, et al. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma. Arch Pathol Lab Med 2014;138(2):175-8121
   PubMed Web of Science ®Google Scholar
• Santagata S, Thakkar A, Ergonul A, et al. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest 2014;124(2):859-70
   PubMed Web of Science ®Google Scholar
• Almendro V, Kim H, Cheng YK, et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 2014;74(5):1338-48
   PubMed Web of Science ®Google Scholar
• Gangi A, Chung A, Mirocha J, et al. Breast-conserving therapy for triple-negative breast cancer. JAMA Surg 2014;
   Google Scholar
• Gandini S, Guerrieri-Gonzaga A, Pruneri G, et al. Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. Ann Oncol 2014;25(3):618-23
   PubMed Web of Science ®Google Scholar
• Bartsch R, Frings S, Marty M, et al. Present and future breast cancer management–bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. Ann Oncol 2014;25(4):773-80
   PubMed Web of Science ®Google Scholar
• Blamey RW, Pinder SE, Ball GR, et al. Reading the prognosis of the individual with breast cancer. Eur J Cancer 2007;43:1545-154727
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91
   PubMed Web of Science ®Google Scholar
• Hurria A, Wong FL, Villaluna D, et al. Role of age and health in treatment recommendations for older adults with breast cancer: the prespective of oncologists and primary care providers. J Clin Oncol 2008;26:5386-92
   PubMed Web of Science ®Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106:(5). pii: dju055, doi: 10.1093/jnci/dju055
   PubMed Web of Science ®Google Scholar
• Blows M, Driver K, Schmidt M, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7(5):e1000279
   PubMed Web of Science ®Google Scholar
• Saphner T, Tormey D, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14(10):2738-46
   PubMed Web of Science ®Google Scholar
• Azim HA Jr, Michiels S, Bedard PL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 2012;18(5):1341-51
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948-55
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-379633
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-18
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27–a randomized controlled phase III trial. 2013;31(11):1398-404
   Google Scholar
• Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 2008;26:1956-64
   PubMed Web of Science ®Google Scholar
• Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008;26:1972-9
   PubMed Web of Science ®Google Scholar
• Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 2011;12:1101-8
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135-41
   PubMed Web of Science ®Google Scholar
• Enright K, Trudeau ME, Taback N, et al. A population-based assessment of the risk of fragility fracture associated with the use of adjuvant hormone therapy for early breast cancer in older women. J Clin Oncol 2011;29(Suppl)):abstract 519
   Google Scholar
• Jokuszies A, Radtke C, Betzler C, et al. Is tamoxifen associated with an increased risk for thromboembolic complications in patients undergoing microvascular breast reconstruction? Ger Med Sci 2013;11:Doc05
   PubMedGoogle Scholar
• Wong AW, Chan SS, Yeo W, et al. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol 2013;121(5):943-50. Erratum in Obstet Gynecol 2013;122(3):698
   PubMed Web of Science ®Google Scholar
• Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-67
   PubMed Web of Science ®Google Scholar
• Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379(9814):432-44
   PubMed Web of Science ®Google Scholar
• Muss H, Berry D, Cirrincione C, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:2055-65
   PubMed Web of Science ®Google Scholar
• Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: european Cooperative Trials 40. in Operable Breast Cancer. J Clin Oncol 2009;27:2474-81
   PubMed Web of Science ®Google Scholar
• Qin Y-Y, Li H, Guo X-J, et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One 2011;6(11):e2694641
   Google Scholar
• De Laurentiis M, Cancello G, D’Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysisof randomized trials. J Clin Oncol 2008;26(1):44-53
   PubMed Web of Science ®Google Scholar
• Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012;291(1-3):1-9
   PubMed Web of Science ®Google Scholar
• Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011;37(4):300-11
   PubMed Web of Science ®Google Scholar
• Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177-83
   PubMed Web of Science ®Google Scholar
• Peterson DE, Bensadoun R-J, Roila F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22(Suppl 6):vi78-84
   PubMedGoogle Scholar
• Schrijvers D, De Samblanx H, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010;21(Suppl 5):v244-7
   PubMed Web of Science ®Google Scholar
• Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010;21(Suppl 5):v248-51
   PubMed Web of Science ®Google Scholar
• Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 2007;25:3871-6
   PubMed Web of Science ®Google Scholar
• Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4- year follow-up of a randomised controlled trial. Lancet Oncol 2011;12:236-24449
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2- positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B- 31. J Clin Oncol 2011;29:3366-73
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2- positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27:5700-6
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-44
   PubMed Web of Science ®Google Scholar
• Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322-9
   PubMed Web of Science ®Google Scholar
• Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900-2
   PubMed Web of Science ®Google Scholar
• Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-15
   PubMed Web of Science ®Google Scholar
• Telli ML, Hunt SA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:3525-33
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21
   PubMed Web of Science ®Google Scholar
• Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-19
   PubMed Web of Science ®Google Scholar
• Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25:3859-65
   PubMed Web of Science ®Google Scholar
• Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231-8
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapyin HER2-positive breast cancer. N Eng J Med 2005;353:1659-72
   PubMed Web of Science ®Google Scholar
• Jones AL, M Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009;100:684-92
   PubMed Web of Science ®Google Scholar
• Serrano C, Cortés J, De Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012;23(4):897-902
   PubMed Web of Science ®Google Scholar
• Ezaz G, Long JB, Gross CP, et al. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 2014;3(1):e000472
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20
   PubMed Web of Science ®Google Scholar
• Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2- positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40
   PubMed Web of Science ®Google Scholar
• Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2- positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012;30:1989-95
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial. Lancet Oncol 2012;13:25-32
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? ; a critical literature review and meta analysis. Expert Opin Drug Saf 2014;13(8):999-1008
   PubMed Web of Science ®Google Scholar
• Azim HA Jr, Agbor-Tarh D, Bradbury I, et al. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol 2013;31(36):4504-11
   PubMed Web of Science ®Google Scholar
• Hadji P, Bundred N. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Semin Oncol 2007;34(6 Suppl 4):S4-10
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Abdel-Wahab M, Shaker M, et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013;30(3):655
   PubMed Web of Science ®Google Scholar
• Azim HA, Kamal NS, Malak RA. Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate! J Thorac Dis. 2013;5(Suppl 1):S27-35
   Google Scholar
• Coleman R, Gnant M, Paterson A, et al. On Behalf of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)’s Bisphosphonate Working Group. Sheffield Cancer Research Centre. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials. Abstract number [S4-07]. Proceedings of SABCs; 2013. Available from: www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_3045&terms=, accessed online on 13/2/2014
   Google Scholar
• Guimarães EP, Pedreira FR, Jham BC, et al. Clinical management of suppurative osteomyelitis, bisphosphonate-related osteonecrosis, andosteoradionecrosis: report of three cases and review of the literature. Case Rep Dent 2013;2013:402096
   Google Scholar
• Schonberg M, Marcantonio E, Ngo L, et al. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol 2011;29:1570-7
   PubMed Web of Science ®Google Scholar
• Janisch L, Mick R, Schilsky RL, et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 1994;74(7):1965-73
   PubMed Web of Science ®Google Scholar
• Torres OH, Munoz J, Ruiz D, et al. Outcome predictors of pneumonia in elderly patients: the importance of functional assessment. J Am Geriatr Soc 2004;52:1603-9
   PubMed Web of Science ®Google Scholar
• Land LH, Dalton SO, Jensen MB, et al. Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br J Cancer 2012;107(11):1901-7
   PubMed Web of Science ®Google Scholar
• Ellis G, Whitehead MA, O’Neill D, et al. Comprehensive geriatric assessment for older adults admitted to hospital (Review). Cochrane Database Syst Rev 2011(7):CD006211
   Google Scholar
• Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005;55:241-52
   PubMed Web of Science ®Google Scholar
• Pallis AG, Fortpied C, Wedding U, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 2010;46:1502-13
   PubMed Web of Science ®Google Scholar
• Albrand G, Terret C. Early breast cancer in the elderly - assessment and management considerations. Drugs Aging 2008;25:35-45
   PubMed Web of Science ®Google Scholar
• Gironés R, Torregrosa D, Díaz-Beveridge R. Comorbidity, disability and geriatric syndromes in elderly breast cancer survivors. Results of a single-center experience. Crit Rev Oncol Hematol 2009;17:236-245102
   Google Scholar
• Barthélémy P, Heitz D, Mathelin C, et al. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. Crit Rev Oncol Hematol 2011;79:196-204
   PubMed Web of Science ®Google Scholar
• Taira N, Masataka E, Sawaki E, et al. Comprehensive geriatric assessment in elderly breast cancer patients. Breast Cancer 2010;17:183-9
   PubMed Web of Science ®Google Scholar
• Johnston SJ, Kenney FS, Syed BM, et al. A andomized trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Ann Oncol Off J Eur Soc Med Oncol 2012;23(9):2296-300
   PubMed Web of Science ®Google Scholar
• Inal A, Akman T, Yaman S, et al. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology). J BUON 2013;18(1):64-9
   PubMed Web of Science ®Google Scholar
• Kornblith AB, Lan L, Archer L, et al. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. J Clin Oncol 2011;29:1022-8
   PubMed Web of Science ®Google Scholar
• Sawaki M, Mukai H, Tokudome N, et al. Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. Breast Cancer 2012;19:253-8
   PubMed Web of Science ®Google Scholar
• Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 2007;25:3699-704
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 2013;31:4222-8
   PubMed Web of Science ®Google Scholar
• Adamo V, Ricciardi GRR, Adamo B, et al. Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: a 5-year case series. J Clin Oncol 2012;30(Suppl):abstract e11056
   Google Scholar
• Militello L, Carli P, Spazzapan S, et al. Safety of adjuvant trastuzumab (T) in elderly patients with breast cancer. J Clin Oncol 2011;29(Suppl 27):abstract 282
   Google Scholar
• Freedman RA, Vaz Duarte Luis IM, Lin N, et al. Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC). J Clin Oncol 2013;31(Suppl):abstract 616
   Google Scholar
• Karavasilis V, Pectasides DG, Papadimitriou CA, et al. Safety and tolerability of adjuvant dose dense chemotherapy in elderly patients with node-positive early breast cancer. J Clin Oncol 2013;31(Suppl):abstract 1093
   Google Scholar
• Blaes AH, Chia V, Solid C, et al. Poster Session 1 - Treatment: Toxicities - Management: Patterns of granulocyte colony stimulating factor (G-CSF) use in elderly breast cancer (BC) patients receiving myelosuppressive chemotherapy. Cancer Res 2012;72(24 Suppl):abstract nr P1-15-01
   Google Scholar
• Hara F, Watanabe T, Shimozuma K, et al. Poster Session 1 - Treatment: Chemotherapy – Adjuvant: Efficacy, toxicity and quality of life in older patients with early-stage breast cancer treated with oral Tegafur-uracil or classical CMF (cyclophosphamide, methotrexate, and fluorouracil): an exploratory analysis of National Surgical Adjuvant Study for Breast Cancer (N-SAS BC) 01 Trial. Cancer Res 2012;72(24 Suppl):abstract nr P1-13-10
   Google Scholar
• Kenis C, Decoster L, Bode H, et al. Poster Session 6 - Psychosocial, Quality of Life, and Educational Aspects: Psychosocial, QOL, and Educational Aspects – Other: Impact of comprehensive geriatric assessment on treatment decision and follow-up in older breast cancer patients. Cancer Res 2012;72(24 Suppl):abstract nr P6-09-07
   Google Scholar
• Nätterdal T, Klint L, Holmberg E, et al. Poster Session 6 - Treatment: Adjuvant Therapy – Other: Adjuvant treatment in breast cancer patients aged 70 years or older during three years. a systematic review of patients charts. Cancer Res 2012;72(24 Suppl):Abstract nr P6-12-01
   Google Scholar
• Dall P, Lenzen G, Göhler T, et al. Abstract P2-15-02: Trastuzumab treatment of early breast cancer: Long-term results from a prospective observation study, including a large cohort of elderly patient. Cancer Res 2013;73(24 Suppl):abstract nr P2-15-02
   Google Scholar
• Albain KS, Barlow WE, Ravdin PM, et al. A Randomized trial of adjuvant chemotherapy and tamoxifen timing in postmenopausal, endocrine-responsive, node-positive breast cancer. Lancet 2009;32(9707):2055-63
   Google Scholar
• Stewart AL, Kamberg CJ. Physical functioning measures. In: Stewart AL, Ware JE Jr, editors. Measuring functioning and well-being; the Medical Outcomes Study approach. Duke University Press; Durham, North Carolina: 1992. p. 86-101
   Google Scholar
• Fillenbaum GG, Smyer MA. The development, validity and reliability of the OARS Multidimensional Functional Assessment Questionnaire. J Gerontol 1981;36:428-34
   PubMedGoogle Scholar
• Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. Columbia University Press, New York; 1948. p. 191-205
   Google Scholar
• Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960;11:7-33
   Google Scholar
• Podsialdo D, Richardson S. The timed ‘Up & Go’: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991;39(2):142-8
   PubMed Web of Science ®Google Scholar
• Naeim A, Reuben D. Geriatric syndromes and assessment in older cancer patients. Oncology 2001;15(12):1567
   PubMed Web of Science ®Google Scholar
• Narain P, Rubenstein LZ, Wieland GD, et al. Predictors of immediate and 6 month outcomes in hospitalized elderly patients. The importance of functional status. J Am Geriatr Soc 1988;36:775-83
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Vestal RE. Aging and pharmacology. Cancer 1997;80(7):1302-10
   PubMed Web of Science ®Google Scholar
• Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-10
   PubMed Web of Science ®Google Scholar
• Rinaldi P, Mecococci P, Benedetti C, et al. Validation of the five-item geriatric depression scale in elderly subjects in three different settings. J Am Geriatr Soc 2003;51:694-8
   PubMed Web of Science ®Google Scholar
• Moser A, Stuk AE, Silliman RA, et al. The 8-item modified medical outcomes study social support survey (mMOS-SS): psychometric evaluation shows excellent performance. J Clin Epidemiol 2012;65:1107-16
   PubMed Web of Science ®Google Scholar
• Seeman TE, Berkman LF, Kohout F, et al. Intercommunity variations in the association between social ties and mortality in the elderly. A comparative analysis of three communities. Ann Epidemiol 1993;3:325-35
   PubMedGoogle Scholar
• Landi F, Giuseppe G, Gambassi G, et al. Body mass index and mortality among older people living in the community. J Am Geriatr Soc 1999;47:1072
   PubMed Web of Science ®Google Scholar
• Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;68:491-7
   Google Scholar
• Vellas B, Villars H, Abellan G, et al. Overview of the MNA–Its history and challenges. J Nutr Health Aging 2006;10:456-63
   PubMed Web of Science ®Google Scholar
• Katzman R, Brown T, Fuld P, et al. validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 1983;140:734-9
   PubMed Web of Science ®Google Scholar
• Borson S, Scanlan JM, Chen P, et al. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc 2003;51:1451-4
   PubMed Web of Science ®Google Scholar
• Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001;344:1111-16
   PubMed Web of Science ®Google Scholar
• Stewart AL, Ware JE Jr. Measuring functioning and well-being: the Medical Outcomes Study approach. Duke University Press; Durham, NC: 1992
   Google Scholar